IDEX Corporation — FY2022 Form 10-K
Business context and reporting period. IDEX is a global manufacturer of specialized fluid and metering, health and science, and fire, safety and diversified products. This annual report covers the fiscal year ended December 31, 2022; it is not a standalone fourth-quarter report. Sales were split across Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). Approximately 48% of sales were to customers outside the U.S.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Net sales | $3,181.9 million | $2,764.8 million | +15%; organic sales +13% |
| Gross margin | 44.8% | 44.3% | +50 bps |
| Operating income / margin | $751.4 million / 23.6% | $637.0 million / 23.0% | Income +18%; margin +60 bps |
| Net income attributable to IDEX | $586.9 million | $449.4 million | +31% |
| Diluted EPS attributable to IDEX | $7.71 | $5.88 | +31% |
| Adjusted diluted EPS (non-GAAP) | $8.12 | $6.87 | +18% |
| Adjusted EBITDA / margin (non-GAAP) | $884.2 million / 27.9% | $765.4 million / 27.7% | +16%; margin +20 bps |
| Operating cash flow | $557.4 million | $565.3 million | Down $7.9 million |
| Free cash flow (non-GAAP) | $489.4 million | $492.6 million | Down $3.2 million |
Management attributed stronger organic operating results primarily to volume leverage, pricing relative to costs, and productivity; inflation-related employee costs, discretionary spending, and resource investments offset some gains. Adjusted EBITDA and adjusted EPS are non-GAAP measures and should be considered alongside GAAP results.
Segments: FMT sales were $1,167.3 million (+17%) and Adjusted EBITDA was $374.2 million (+26%), with margin of 32.1% (+240 bps). HST sales were $1,339.2 million (+19%) and Adjusted EBITDA was $411.8 million (+16%), with margin of 31.2% (down 50 bps). FSDP sales were $679.2 million (+5%) and Adjusted EBITDA was $183.9 million (down 1%), with margin of 27.1% (down 160 bps). Currency translation was unfavorable to sales across all three segments.
Liquidity and debt: Cash and cash equivalents were $430.2 million at year-end, down from $855.4 million. Working capital was $855.7 million and the current ratio was 2.6. Gross borrowings totaled $1,477.8 million; $277.7 million was floating-rate debt. The $800 million revolving facility had $77.7 million drawn and $714.4 million of net available capacity, including the effect of letters of credit. The company had $100 million of 3.20% notes due June 2023 and expected to refinance or repay them using revolving capacity. It reported compliance with debt covenants, with a 1.55x leverage ratio against a 3.50x maximum.
Operating cash flow was pressured by working-capital investment: operating working capital rose $156.8 million to $704.8 million, including increased receivables and inventories. Capital expenditures were $68.0 million. The company spent $945.6 million, net of cash acquired, on acquisitions, repurchased $148.1 million of shares, and paid $177.4 million in dividends. The quarterly dividend increased 11% to $0.60 per share.
Material changes versus FY2021
- Sales growth reflected 13% organic growth, a 5% net contribution from acquisitions and divestitures, a 1% contribution from accelerated COVID-19 application revenue, and a 4% adverse currency effect.
- FY2022 acquisitions were Nexsight, KZValve, and Muon Group. Muon Group was acquired for $713.0 million, partly funded with $370.4 million of borrowings. IDEX sold Knight for $49.4 million in proceeds and recorded a $34.8 million pretax gain.
- Cash from operations was slightly lower despite higher earnings, as working-capital needs increased. Cash used in investing activities rose to $917.2 million, primarily reflecting acquisitions.
- In Q4, IDEX changed its segment performance measure used by the chief operating decision maker from operating income to Adjusted EBITDA.
Outlook, commentary, risks, and unusual items
Management gave no specific quantitative FY2023 revenue or earnings guidance in the supplied filing text. Its stated 2023 priorities were foundational execution, developing global teams, and continued capital deployment. It expected organic investment opportunities to be in line with 2022 spending and cited capacity, cash generation, and balance-sheet capacity to pursue acquisitions.
- Unusual COVID-19 item: A customer discontinued investment in a COVID-19 testing application. IDEX recognized $17.9 million of previously deferred revenue and recorded a $16.8 million asset impairment. Management excludes the net effect from certain adjusted measures.
- Principal risks: economic and industrial slowdowns; inflation, pricing and interest-rate changes; supply-chain, materials, labor and capacity constraints; foreign-exchange and geopolitical exposure; acquisition execution and integration; cybersecurity; regulatory and climate-related changes; and litigation or other contingencies.
- Contingencies: IDEX disclosed ordinary-course legal matters and asbestos-related claims. It stated that most resolved asbestos claims had been dismissed without payment or settled for immaterial amounts, largely covered by insurance, and did not expect a material adverse effect. Future insurance coverage remains uncertain.
- Asset and audit considerations: Goodwill was $2,638.1 million and intangible assets were $947.8 million. The annual impairment test found reporting-unit fair values substantially above carrying values. The auditor issued unqualified opinions on the financial statements and internal controls; controls at the three 2022 acquisitions were excluded from management’s assessment.
Most important facts for investors to verify
- Whether organic growth, pricing and segment margins remain resilient as supply constraints, inflation, and end-market conditions change.
- Whether the acquired businesses—particularly Muon Group—deliver expected growth and returns, and whether acquisition-related amortization and debt remain manageable.
- How working capital and cash conversion develop after the FY2022 increase in receivables and inventories.
- How IDEX refinanced or repaid the $100 million notes due June 2023, and the subsequent level and cost of floating-rate debt.
- Whether the COVID-19 application exit, litigation and insurance matters, or goodwill and intangible-asset assumptions lead to further charges or exposures.